Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4739983
Max Phase: Preclinical
Molecular Formula: C41H42N4O12S3
Molecular Weight: 879.00
Molecule Type: Unknown
Associated Items:
ID: ALA4739983
Max Phase: Preclinical
Molecular Formula: C41H42N4O12S3
Molecular Weight: 879.00
Molecule Type: Unknown
Associated Items:
Canonical SMILES: COc1ccc(S(=O)(=O)NC(=O)CN(c2cccc3c2CCN3C(C(=O)NS(=O)(=O)c2ccc(C)cc2OC)c2cccc(OC)c2)S(=O)(=O)c2ccc(OC)cc2)cc1
Standard InChI: InChI=1S/C41H42N4O12S3/c1-27-12-21-38(37(24-27)57-5)59(50,51)43-41(47)40(28-8-6-9-31(25-28)56-4)44-23-22-34-35(44)10-7-11-36(34)45(60(52,53)33-19-15-30(55-3)16-20-33)26-39(46)42-58(48,49)32-17-13-29(54-2)14-18-32/h6-21,24-25,40H,22-23,26H2,1-5H3,(H,42,46)(H,43,47)
Standard InChI Key: JTDWZQZKKFDOFM-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 879.00 | Molecular Weight (Monoisotopic): 878.1961 | AlogP: 4.34 | #Rotatable Bonds: 16 |
Polar Surface Area: 204.02 | Molecular Species: ACID | HBA: 13 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 16 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 3.67 | CX Basic pKa: | CX LogP: 5.19 | CX LogD: 3.31 |
Aromatic Rings: 5 | Heavy Atoms: 60 | QED Weighted: 0.14 | Np Likeness Score: -0.98 |
1. Zhou HS,Hu LB,Zhang H,Shan WX,Wang Y,Li X,Liu T,Zhao J,You QD,Jiang ZY. (2020) Design, Synthesis, and Structure-Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors., 63 (19.0): [PMID:32902980] [10.1021/acs.jmedchem.0c01116] |
2. Narayanan D, Tran KT, Pallesen JS, Solbak SMØ, Qin Y, Mukminova E, Luchini M, Vasilyeva KO, González Chichón D, Goutsiou G, Poulsen C, Haapanen N, Popowicz GM, Sattler M, Olagnier D, Gajhede M, Bach A.. (2022) Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery., 65 (21.0): [PMID:36263945] [10.1021/acs.jmedchem.2c00830] |
Source(1):